Skip to main content

Massive Transfusion

0
Pipeline Programs
3
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

CSL Behring
CSL BehringIL - Bradley
1 program
Australian and New Zealand Massive Transfusion RegistryN/A
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Australian and New Zealand Massive Transfusion RegistryN/A1 trial
Active Trials
NCT02863250Recruiting50,000Est. Dec 2028
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
Australian and New Zealand Massive Transfusion RegistryN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Human BioSciencesAustralian and New Zealand Massive Transfusion Registry

Clinical Trials (1)

Total enrollment: 50,000 patients across 1 trials

NCT02863250Human BioSciencesAustralian and New Zealand Massive Transfusion Registry

Australian and New Zealand Massive Transfusion Registry

Start: Mar 2011Est. completion: Dec 202850,000 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 50,000 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.